Anti-hair loss efficacy testing substantiates cosmetic claims through controlled human trials, instrumental scalp analysis, and safety evaluation performed by accredited third-party laboratories. This technical guide explains the regulatory framework, sample types, key endpoints such as hair density and shedding rate, and the testing methods required before an anti-hair loss claim can be legally marketed.
Technical Overview
Anti-hair loss efficacy testing is the scientific process used to verify whether a cosmetic product measurably reduces hair shedding, improves hair density or hair shaft thickness, or enhances the scalp conditions associated with excessive hair loss. Because hair loss claims directly influence consumer purchasing decisions and personal health perceptions, they are among the most heavily regulated functional claims in the cosmetics industry.
In China, the Cosmetic Supervision and Administration Regulation (CSAR), effective January 1, 2021, together with the NMPA Cosmetic Efficacy Claim Evaluation Standards effective May 1, 2021, classifies anti-hair loss as a specific efficacy claim that must be substantiated through human efficacy trials. Literature review, in vitro data, consumer surveys, or laboratory research alone are not sufficient to support this claim. The efficacy claim summary must be uploaded to the designated national regulatory platform and disclosed to the public.
The scientific rationale for testing is grounded in the hair growth cycle, which consists of the anagen (growth), catagen (transition), and telogen (resting) phases. Common hair loss patterns, such as androgenetic alopecia, involve the conversion of testosterone to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, leading to shortened anagen duration, follicular miniaturization, and increased telogen shedding. Cosmetic anti-hair loss products are formulated to cleanse the scalp, regulate sebum, reduce oxidative stress, strengthen the hair shaft, and decrease shedding, but they are not permitted to claim treatment of alopecia as a medical condition.
Testing is therefore designed around objective, quantifiable endpoints measured under standardized and controlled conditions, with statistical comparison against baseline values and, in most rigorous protocols, against a vehicle or placebo control.
Testing Samples
Rinse-Off Products: Anti-Hair Loss Shampoos and Scalp Cleansers
Shampoos formulated with active ingredients such as caffeine, botanical extracts, peptides, zinc derivatives, or anti-dandruff actives are the most common rinse-off samples submitted for testing. Because rinse-off products have limited contact time with the scalp, trials must follow the actual recommended use conditions, including application frequency, massage duration, and rinsing procedure. Submission typically requires 40 to 80 consumer units of the finished product along with matching placebo formulations.
Leave-On Products: Scalp Serums, Tonics, and Essences
Leave-on products, including scalp serums, ampoules, tonics, and essences, are the most frequently tested category because sustained contact with the scalp improves the plausibility of efficacy. Samples must be submitted in their final market packaging together with the complete ingredient list, usage instructions, and placebo vehicles that match the base formula without the active ingredients.
Conditioners, Hair Masks, and Scalp Sprays
Conditioners, masks, and scalp sprays claiming to reduce hair fall due to breakage or to improve scalp condition may also undergo efficacy testing. For these products, the test protocol must reflect realistic consumer application, and endpoints may emphasize hair shaft strength, breakage reduction, and combing-force reduction in addition to scalp-based measurements.
Active Ingredients and Raw Materials
Raw materials and functional actives, such as plant extracts, peptides, caffeine derivatives, and microbiome-regulating compounds, are commonly screened through in vitro and ex vivo methods before being incorporated into finished products. Pre-screening helps formulators prioritize candidates for the more expensive human efficacy trials.
Testing Items
Efficacy evaluation for anti-hair loss products is built on a matrix of instrumental, dermatological, and subjective endpoints. Core testing items include:
- Total hair density in a defined target scalp area, expressed as hairs per square centimeter
- Terminal hair count and vellus hair count, reflecting follicular miniaturization status
- Average hair shaft diameter and diameter distribution
- Anagen hair ratio and anagen-to-telogen ratio as indicators of growth cycle normalization
- Hair growth rate measured in millimeters per day
- Standardized hair shedding counts, including the 60-second combing test and the wash collection test
- Hair pull test positivity rate assessed by a dermatologist
- Scalp sebum casual level, scalp hydration, and transepidermal water loss (TEWL)
- Dandruff, erythema, and scalp inflammation grading using standardized scales
- Standardized global photography for macroscopic visual comparison
- Subject self-assessment questionnaires and dermatologist global efficacy assessment
Safety items conducted alongside efficacy evaluation include in-use scalp tolerance monitoring for erythema, pruritus, and folliculitis; human repeated insult patch testing (HRIPT) for sensitization potential; and verification of microbiological limits and heavy metal content in accordance with the Safety and Technical Standards for Cosmetics (2015 Edition).
Testing Methods
Human Efficacy Trial: Phototrichogram and Trichoscopy
The human efficacy trial is the core method for substantiating anti-hair loss claims. A typical protocol is a randomized, investigator-blinded, placebo-controlled, parallel-group study enrolling at least 30 valid subjects per group, usually men and women aged 18 to 60 with mild to moderate androgenetic alopecia, classified as Hamilton-Norwood stages II to IV for men or Ludwig stages I to II for women. Subjects with active scalp disease, or those who used hair loss medications within the previous three to six months, are excluded.
A target area on the scalp, commonly one square centimeter, is marked with a semi-permanent tattoo point or reusable template to guarantee that the identical region is imaged at each visit. High-resolution trichoscopy or phototrichogram imaging is performed at baseline, at intermediate checkpoints, and at the end of the use period, which typically ranges from 8 to 24 weeks to cover at least one complete hair cycle. Automated or manual image analysis quantifies hair density, hair diameter, and anagen ratio. All measurements are conducted under standardized conditions, including controlled temperature and humidity, identical lighting, and a required shampoo-free interval of 24 to 48 hours before each assessment.
Statistical analysis compares values at each time point against baseline using paired tests and compares the test product against the placebo group using between-group analysis, with a significance threshold conventionally set at p less than 0.05.
Hair Shedding Quantification Methods
Shedding reduction is a primary consumer-perceivable endpoint. The 60-second standardized combing test requires subjects to comb their hair over a collection sheet with a standardized comb and technique for 60 seconds on three consecutive mornings; the shed hairs are then counted by trained personnel. The wash collection test gathers and counts all hairs lost during a standardized shampooing session under supervision. Daily shedding diaries maintained by subjects provide supplementary longitudinal data.
In Vitro and Ex Vivo Supporting Methods
Although not sufficient alone for claim substantiation, laboratory methods provide mechanistic support and formulation screening. Common assays include:
- Human hair follicle organ culture, measuring hair shaft elongation in isolated anagen follicles over 7 to 14 days
- Dermal papilla cell and outer root sheath keratinocyte proliferation assays using MTT or CCK-8 viability detection
- 5-alpha reductase inhibition assays quantifying the reduction of DHT formation
- Anti-inflammatory assays measuring markers such as interleukin-6 and prostaglandin E2 in stimulated cell models
- Antioxidant capacity and scalp microbiome modulation assays
Scalp Condition and Safety Evaluation
Instrumental scalp assessment using sebumetry, corneometry, and mexametry documents changes in sebum secretion, hydration, and erythema. Throughout the trial, dermatological supervision records all adverse events, and patch testing conducted according to recognized protocols supports the sensitization safety profile of the finished product.
Applications
Anti-hair loss testing results serve multiple regulatory and commercial purposes across the product lifecycle:
- Regulatory compliance in China, where the efficacy claim summary must be compiled and uploaded to the designated NMPA platform for public disclosure before marketing
- Advertising law compliance, ensuring that claims such as reduces hair loss, decreases shedding, and improves scalp condition are supported by adequate evidence
- International market access, including substantiation under the EU common criteria for cosmetic claims defined in Regulation (EC) No 655/2013 and reasonable basis documentation expected in other jurisdictions
- Research and development support, including active ingredient screening, dose-response optimization, and formulation ranking
- Competitive benchmarking and substantiated marketing collateral for e-commerce, retail, and professional channels
Brands that invest in properly designed testing reduce the risk of regulatory penalties, advertising disputes, and reputational damage while strengthening consumer trust in their hair care lines.
FAQ
Is human efficacy testing mandatory for anti-hair loss claims in China?
Yes. Under the NMPA Cosmetic Efficacy Claim Evaluation Standards, an anti-hair loss claim must be supported by a human efficacy trial conducted by a qualified evaluation institution. Supporting data such as in vitro studies or literature may supplement, but cannot replace, the human trial.
How long does an anti-hair loss efficacy test take?
The subject-use period typically ranges from 8 to 24 weeks, with 12 to 16 weeks being common for cycle-related endpoints. Including recruitment, baseline stabilization, and reporting, the complete study usually requires three to six months.
How many subjects are required?
Chinese guidance generally requires at least 30 valid subjects per group for anti-hair loss human trials. Larger sample sizes improve statistical power and are recommended for products intended for global claim portfolios.
Can a rinse-off shampoo support an anti-hair loss claim?
Yes, provided the trial follows the product's real use conditions, including contact time and application frequency. The formulation must be capable of delivering functional actives to the scalp within the rinse-off window.
How do cosmetic anti-hair loss claims differ from drug claims?
Cosmetics may claim reduction of shedding due to breakage, scalp environment improvement, and hair strengthening, but may not claim to treat, cure, or diagnose alopecia, nor claim hair regrowth equivalent to pharmaceutical products. Claim wording must stay within cosmetic functional boundaries.
Where must the test results be filed?
In China, the efficacy claim summary based on the human trial must be uploaded to the designated national platform for public disclosure, allowing consumers and regulators to verify the basis of the anti-hair loss claim.